☰

William Raj Sellers, M.D. - Publications

Affiliations: 
Novartis, Basel, Basel-Stadt, France 
 Dana-Farber Cancer Institute and Harvard Medical School, USA 
 Broad Institute - Cancer Program 
Area:
oncology
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

245 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M. Correction: Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. Plos Medicine. 21: e1004470. PMID 39284164 DOI: 10.1371/journal.pmed.1004470  0.38
2024 Vijay V, Karisani N, Shi L, Hung YH, Vu P, Kattel P, Kenney L, Merritt J, Adil R, Wu Q, Zhen Y, Morris R, Kreuzer J, Kathiresan M, Herrera Lopez XI, ... ... Sellers WR, et al. Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets. Biorxiv : the Preprint Server For Biology. PMID 39026794 DOI: 10.1101/2024.07.04.601970  0.337
2024 Chang L, Jung NY, Atari A, Rodriguez DJ, Kesar D, Song TY, Rees MG, Ronan M, Li R, Ruiz P, Chaturantabut S, Ito T, van Tienen LM, Tseng YY, Roth JA, ... Sellers WR, et al. Author Correction: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nature Genetics. PMID 38396071 DOI: 10.1038/s41588-024-01680-3  0.766
2023 Chang L, Jung NY, Atari A, Rodriguez DJ, Kesar D, Song TY, Rees MG, Ronan M, Li R, Ruiz P, Chaturantabut S, Ito T, van Tienen LM, Tseng YY, Roth JA, ... Sellers WR, et al. Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nature Genetics. PMID 37749246 DOI: 10.1038/s41588-023-01515-7  0.815
2023 Tiedt R, King FJ, Stamm C, Niederst MJ, Delach S, Zumstein-Mecker S, Meltzer J, Mulford IJ, Labrot E, Engstler BS, Baltschukat S, Kerr G, Golji J, Wyss D, Schnell C, ... ... Sellers WR, et al. Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Reports. 42: 112297. PMID 36961816 DOI: 10.1016/j.celrep.2023.112297  0.693
2022 Bondeson DP, Mullin-Bernstein Z, Oliver S, Skipper TA, Atack TC, Bick N, Ching M, Guirguis AA, Kwon J, Langan C, Millson D, Paolella BR, Tran K, Wie SJ, Vazquez F, ... ... Sellers WR, et al. Systematic profiling of conditional degron tag technologies for target validation studies. Nature Communications. 13: 5495. PMID 36127368 DOI: 10.1038/s41467-022-33246-4  0.654
2022 Cantor SB, Sellers WR, Pathania S, Greenberg RA. David Livingston (1941-2021). Molecular Cell. 82: 4-7. PMID 34995508 DOI: 10.1016/j.molcel.2021.12.013  0.587
2021 Ito T, Young MJ, Li R, Jain S, Wernitznig A, Krill-Burger JM, Lemke CT, Monducci D, Rodriguez DJ, Chang L, Dutta S, Pal D, Paolella BR, Rothberg MV, Root DE, ... ... Sellers WR, et al. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nature Genetics. PMID 34857952 DOI: 10.1038/s41588-021-00967-z  0.721
2020 LaMarche MJ, Acker MG, Argintaru A, Bauer D, Boisclair J, Chan H, Chen C, Chen YP, Chen Z, Deng Z, Doré M, Dunstan D, Fan J, Fekkes P, Firestone B, ... ... Sellers WR, et al. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry. PMID 32910655 DOI: 10.1021/Acs.Jmedchem.0C01170  0.382
2020 Palmer AC, Plana D, Gao H, Korn JM, Yang G, Green J, Zhang X, Velazquez R, McLaughlin ME, Ruddy DA, Kowal C, Goldovitz J, Bullock C, Rivera S, Rakiec DP, ... ... Sellers WR, et al. A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts. Cancer Research. PMID 32747364 DOI: 10.1158/0008-5472.Can-19-3850  0.411
2020 Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER, Kalocsay M, Jané-Valbuena J, Gelfand E, Schweppe DK, Jedrychowski M, Golji J, Porter DA, Rejtar T, Wang YK, Kryukov GV, ... ... Sellers WR, et al. Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell. 180: 387-402.e16. PMID 31978347 DOI: 10.1016/J.Cell.2019.12.023  0.575
2020 Cleary JM, Raghavan S, Li YY, Spurr L, Wu Q, Shi L, Brais LK, Odhiambo Z, Goyal L, Patel AK, Shinagare AB, Clancy TE, Shapiro G, Cerami E, Sellers WR, et al. Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 38: 567-567. DOI: 10.1200/Jco.2020.38.4_Suppl.567  0.524
2020 Wernitznig A, Lipp JJ, Zichner T, Gerlach D, Bauer MJ, Voss T, Schlattl A, Haslinger C, Montgomery PG, Zamanighomi M, Sellers WR, Kraut N. Abstract 3227: CLIFF, a bioinformatics software tool to explore molecular differences between two sets of cancer cell lines Cancer Research. 80: 3227-3227. DOI: 10.1158/1538-7445.Am2020-3227  0.462
2020 Weiss A, Stauffer F, Clemens C, Möbitz H, Ragot C, Beyer KS, Calkins K, Thoma C, Guthy D, Kiffe M, Eerdenbrugh BV, Sellers WR, Hofmann F, Tiedt R, Gaul C. Abstract 1770: A new DOT1L inhibitor with in vivo activity in mouse models of MLL-translocated leukemia Cancer Research. 80: 1770-1770. DOI: 10.1158/1538-7445.Am2020-1770  0.367
2020 Li YY, Cleary JM, Raghavan S, Spurr LF, Wu Q, Shi L, Brais LK, Loftus M, Goyal L, Patel AK, Shinagare AB, Clancy TE, Shapiro G, Cerami E, Sellers WR, et al. Abstract 1097: FGFR2 in-frame indels: A novel targetable alteration in intrahepatic cholangiocarcinoma Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1097  0.458
2019 Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, ... ... Sellers WR, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications. 10: 4346. PMID 31554815 DOI: 10.1038/S41467-019-12361-9  0.629
2019 Weiss A, Adler F, Buhles A, Stamm C, Fairhurst RA, Kiffe M, Sterker D, Centeleghe M, Wartmann M, Kinyamu-Akunda J, Schadt HS, Couttet P, Wolf A, Wang Y, Barzaghi-Rinaudo P, ... ... Sellers WR, et al. FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer. Molecular Cancer Therapeutics. PMID 31409633 DOI: 10.1158/1535-7163.Mct-18-1291  0.334
2019 Li H, Ning S, Ghandi M, Kryukov GV, Gopal S, Deik A, Souza A, Pierce K, Keskula P, Hernandez D, Ann J, Shkoza D, Apfel V, Zou Y, Vazquez F, ... ... Sellers WR, et al. The landscape of cancer cell line metabolism. Nature Medicine. 25: 850-860. PMID 31068703 DOI: 10.1038/S41591-019-0404-8  0.756
2019 Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, ... ... Sellers WR, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID 31068700 DOI: 10.1038/S41586-019-1186-3  0.817
2019 Ramurthy S, Taft BR, Aversa RJ, Barsanti P, Burger MT, Lou Y, Nishiguchi G, Rico A, Setti L, Smith A, Subramanian S, Tamez VNA, Tanner HR, Wan L, Hu C, ... ... Sellers WR, et al. Design and Discovery of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (LXH254)- A selective, efficacious and well-tolerated RAF inhibitor targeting RAS mutant cancers: The path to the clinic. Journal of Medicinal Chemistry. PMID 31059256 DOI: 10.1021/Acs.Jmedchem.9B00161  0.346
2019 Baltschukat S, Schacher Engstler B, Huang A, Hao HX, Tam A, Wang HQ, Liang J, DiMare MT, Bhang HC, Wang Y, Furet P, Sellers WR, Hofmann F, Schoepfer J, Tiedt R. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of Activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30674502 DOI: 10.1158/1078-0432.Ccr-18-2814  0.386
2019 Sellers W. Abstract CN03-01: Functional genomics approaches to the discovery of paralog dependencies in cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Cn03-01  0.486
2018 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Sellers WR, et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. PMID 30559381 DOI: 10.1038/S41586-018-0722-X  0.764
2018 Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, Haas K, Engstler BS, Cao A, Pinzon-Ortiz M, Mulford I, Acker MG, Chopra R, Brain C, di Tomaso E, ... Sellers WR, et al. The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget. 9: 35226-35240. PMID 30443290 DOI: 10.18632/Oncotarget.26215  0.413
2018 Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, ... ... Sellers WR, et al. TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Reports. 25: 1255-1267.e5. PMID 30380416 DOI: 10.1016/J.Celrep.2018.10.023  0.592
2018 Jeay S, Ferretti S, Holzer P, Fuchs J, Chapeau EA, Wartmann M, Sterker D, Romanet V, Murakami M, Kerr G, Durand EY, Gaulis S, Cortes-Cros M, Ruetz S, Stachyra TM, ... ... Sellers WR, et al. Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201. Cancer Research. PMID 30135191 DOI: 10.1158/0008-5472.Can-18-0338  0.309
2018 Abrams TJ, Connor A, Fanton CP, Cohen SB, Huber T, Miller K, Hong EE, Niu X, Kline J, Ison-Dugenny M, Harris S, Walker DB, Krauser KR, Galimi F, Wang Z, ... ... Sellers WR, et al. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody Drug Conjugate against Mutant and Wild Type c-KIT Positive Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29764854 DOI: 10.1158/1078-0432.Ccr-17-3795  0.355
2018 Shao W, Mishina Y, Feng Y, Caponigro G, Cooke VG, Rivera S, Wang Y, Shen F, Korn JM, Mathews Griner L, Nishiguchi G, Rico A, Tellew J, Haling J, Aversa R, ... ... Sellers WR, et al. Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF. Cancer Research. PMID 29343524 DOI: 10.1158/0008-5472.Can-17-2033  0.394
2018 Stuart DD, Shao W, Mishina Y, Feng Y, Caponigro G, Cooke VG, Rivera S, Shen F, Korn J, Griner LAM, Nishiguchi G, Taft B, Wan L, Subramanian S, Lou Y, ... ... Sellers WR, et al. Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ddt01-04  0.435
2018 Weiss A, Radimerski T, Wyss D, Andraos R, Buhles A, Sterker D, Quancard J, Pissot C, Simic O, Bigaud M, Bornancin F, Schlapbach A, Regnier C, McSheehy P, Buchdunger E, ... ... Sellers W, et al. Abstract 1879: Pyrazolopyrimidines as novel selective allosteric MALT1 inhibitors with in vivo activity in ABC-DLBCL Cancer Research. 78: 1879-1879. DOI: 10.1158/1538-7445.Am2018-1879  0.407
2017 Tripathy D, Bardia A, Sellers WR. Mechanism of Action and Clinical Impact of Ribociclib-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 5658. PMID 28916619 DOI: 10.1158/1078-0432.Ccr-17-1819  0.304
2017 McDonald ER, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, ... ... Sellers WR, et al. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell. 170: 577-592.e10. PMID 28753431 DOI: 10.1016/J.Cell.2017.07.005  0.46
2017 Bialucha CU, Collins SD, Li X, Saxena P, Zhang X, Dürr C, LaFont B, Prieur P, Shim Y, Mosher R, Lee D, Ostrom L, Hu T, Bilic S, Liric Rajlic I, ... ... Sellers WR, et al. Discovery and Optimization of HKT288, a Cadherin-6 Targeting ADC for the Treatment of Ovarian and Renal Cancer. Cancer Discovery. PMID 28526733 DOI: 10.1158/2159-8290.Cd-16-1414  0.409
2017 Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, et al. Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models. Elife. 6. PMID 28425916 DOI: 10.7554/Elife.17137  0.388
2017 Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28351928 DOI: 10.1158/1078-0432.Ccr-16-3157  0.391
2017 Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, ... ... Sellers WR, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. PMID 28329763 DOI: 10.1038/Nature21702  0.334
2017 Chapeau EA, Gembarska A, Durand EY, Mandon E, Estadieu C, Romanet V, Wiesmann M, Tiedt R, Lehar J, de Weck A, Rad R, Barys L, Jeay S, Ferretti S, Kauffmann A, ... ... Sellers WR, et al. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf(-/-) mouse model. Proceedings of the National Academy of Sciences of the United States of America. PMID 28265066 DOI: 10.1073/Pnas.1620262114  0.395
2017 Sellers W. Abstract IA01: The discovery of next-generation cancer targets and therapeutics Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-Ia01  0.529
2017 Porta DG, Weiss A, Fairhurst RA, Wartmann M, Stamm C, Reimann F, Buhles A, Kinyamu-Akunda J, Sterker D, Murakami M, Wang Y, Engelman J, Hofmann F, Sellers WR. Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC Cancer Research. 77: 2098-2098. DOI: 10.1158/1538-7445.Am2017-2098  0.379
2017 Acker MG, Chen YP, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, LaRochelle JR, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Feng F, Firestone B, ... ... Sellers WR, et al. Abstract 2084: Conformational activation and allosteric inhibition of SHP2 in RTK-driven cancers Cancer Research. 77: 2084-2084. DOI: 10.1158/1538-7445.Am2017-2084  0.441
2016 Dafflon C, Craig VJ, Méreau H, Gräsel J, Engstler BS, Hoffman G, Nigsch F, Gaulis S, Barys L, Ito M, Aguadé-Gorgorió J, Bornhauser B, Bourquin JP, Proske A, Stork-Fux C, ... ... Sellers WR, et al. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia. PMID 27840424 DOI: 10.1038/Leu.2016.327  0.383
2016 Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Sellers WR, Schlegel R, Porter D, Morris E, Wuerthner J, Jeay S, Greshock J, et al. High order drug combinations are required to effectively kill colorectal cancer cells. Cancer Research. PMID 27659046 DOI: 10.1158/0008-5472.Can-15-3425  0.569
2016 Chen YP, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, ... ... Sellers WR, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. PMID 27362227 DOI: 10.1038/Nature18621  0.442
2016 Garcia Fortanet J, Chen CH, Chen YP, Chen Z, Deng Z, Firestone B, Fekkes P, Fodor M, Fortin PD, Fridrich C, Grunenfelder D, Ho S, Kang ZB, Karki R, Kato M, ... ... Sellers WR, et al. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. Journal of Medicinal Chemistry. PMID 27347692 DOI: 10.1021/Acs.Jmedchem.6B00680  0.36
2016 Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, DeWeck A, Abramowski D, Wan J, Shirley MD, Neshat SY, ... ... Sellers WR, et al. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discovery. PMID 27260157 DOI: 10.1158/2159-8290.Cd-16-0178  0.421
2016 Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, ... ... Sellers WR, et al. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. Elife. 5. PMID 27183006 DOI: 10.7554/Elife.13964  0.535
2016 Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, Liao RG, Andre F, Banks I, Barrett JC, Caldas C, Camargo AA, Fitzgerald RC, Mao M, Mattison JE, ... ... Sellers WR, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nature Medicine. 22: 464-71. PMID 27149219 DOI: 10.1038/Nm.4089  0.368
2016 Mavrakis KJ, McDonald ER, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, Stump M, deBeaumont R, Ho S, Yue Y, Liu Y, ... ... Sellers WR, et al. Disordered methionine metabolism in MTAP/CDKN2A deleted cancers leads to dependence on PRMT5. Science (New York, N.Y.). PMID 26912361 DOI: 10.1126/Science.Aad5944  0.474
2016 Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, ... ... Sellers WR, et al. Author response: ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor Elife. DOI: 10.7554/Elife.13964.024  0.512
2016 Mavrakis K, McDonald ER, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, McAllister G, deBeaumont R, Ho S, Liu Y, Yan-Neale Y, Yang G, Lin F, ... ... Sellers WR, et al. Abstract LB-017: Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5 Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-017  0.44
2016 Lewin J, Vis DJ, Lawler M, Liao R, Mao M, Teh BT, Sellers W, Ward R, Camargo AA, Andre F, Schilsky R, Lacombe D, Shibata T, Fox S, Tourneau CL, et al. Abstract 1832: Large variations in clinical and ethical aspects of genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey Cancer Research. 76: 1832-1832. DOI: 10.1158/1538-7445.Am2016-1832  0.361
2016 Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Sellers WR, Schlegel R, Porter D, Morris E, Wuerthner J, Jeay S, Greshock J, et al. Abstract 1311: High order drug combinations are required to effectively kill colorectal cancer cells Cancer Research. 76: 1311-1311. DOI: 10.1158/1538-7445.Am2016-1311  0.574
2016 Ferretti S, Rebmann R, Berger M, Santacroce F, Albrecht G, Pollehn K, Sterker D, Wartmann M, Hueber A, Wiesmann M, Jensen MR, Hofmann F, Sellers WR, Holzer P, Jeay S. Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials Cancer Research. 76: 1224-1224. DOI: 10.1158/1538-7445.Am2016-1224  0.323
2015 Huang FW, Bielski CM, Rinne ML, Hahn WC, Sellers WR, Stegmeier F, Garraway LA, Kryukov GV. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 4: e176. PMID 26657580 DOI: 10.1038/oncsis.2015.39  0.538
2015 Herkert B, Kauffmann A, Mollé S, Schnell C, Ferrat T, Voshol H, Juengert J, Erasimus H, Marszalek G, Kazic-Legueux M, Billy E, Ruddy DA, Stump MD, Guthy D, Ristov M, ... ... Sellers WR, et al. Maximizing the efficacy of MAPK-targeted treatment in PTENLOF/BRAFMUT melanoma through PI3K and IGF1R inhibition. Cancer Research. PMID 26577700 DOI: 10.1158/0008-5472.Can-14-3358  0.383
2015 Stransky N, Ghandi M, Kryukov GV, Garraway LA, Lehár J, Liu M, Sonkin D, Kauffmann A, Venkatesan K, Edelman EJ, Riester M, Barretina J, Caponigro G, Schlegel R, Sellers WR, et al. Pharmacogenomic agreement between two cancer cell line data sets Nature. 528: 84-87. PMID 26570998 DOI: 10.1038/Nature15736  0.592
2015 Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, ... ... Sellers WR, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nature Medicine. PMID 26479923 DOI: 10.1038/Nm.3954  0.609
2015 Reddy A, Growney JD, Wilson NS, Emery CM, Johnson JA, Ward R, Monaco KA, Korn J, Monahan JE, Stump MD, Mapa FA, Wilson CJ, Steiger J, Ledell J, Rickles RJ, ... ... Sellers WR, et al. Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages. Plos One. 10: e0138486. PMID 26378449 DOI: 10.1371/Journal.Pone.0138486  0.363
2015 Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, ... ... Sellers WR, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 28: 15-28. PMID 26175413 DOI: 10.1016/J.Ccell.2015.06.006  0.327
2015 Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, Kallen J, Furet P, Gessier F, ... ... Sellers WR, et al. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Elife. 4. PMID 25965177 DOI: 10.7554/Elife.06498  0.409
2015 Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, ... ... Sellers WR, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature Medicine. 21: 440-8. PMID 25849130 DOI: 10.1038/Nm.3841  0.618
2015 Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. Embo Reports. 16: 280-96. PMID 25680965 DOI: 10.15252/Embr.201439949  0.451
2015 Bhang HC, Ruddy DA, Radhakrishna VK, Zhao R, Kao I, Rakiec D, Shaw P, Balak M, Caushi JX, Ackley E, Keen N, Schlabach MR, Palmer M, Sellers WR, Michor F, et al. Abstract 2847: High complexity barcoding to study clonal dynamics in response to cancer therapy Cancer Research. 75: 2847-2847. DOI: 10.1158/1538-7445.Am2015-2847  0.393
2015 Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Halilovic E, Morris E, Sellers WR, Schlegel R, Wuerthner J, Garraway LA, Jeay S, et al. Abstract LB-B04: Complex drug combinations can induce apoptotic killing in robust colorectal cancer cells Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B04  0.568
2015 Schlabach M, Billy E, Mavrakis K, Hoffman G, Schmelzle T, Hofmann F, Keen N, Stegmeier F, Sellers W. Abstract C151: Systematic discovery of cancer dependencies through deep coverage pshRNA screens Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C151  0.436
2014 Huet HA, Growney JD, Johnson JA, Li J, Bilic S, Ostrom L, Zafari M, Kowal C, Yang G, Royo A, Jensen M, Dombrecht B, Meerschaert KR, Kolkman JA, Cromie KD, ... ... Sellers WR, et al. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. Mabs. 6: 1560-70. PMID 25484045 DOI: 10.4161/19420862.2014.975099  0.363
2014 Schoumacher M, Hurov KE, Lehár J, Yan-Neale Y, Mishina Y, Sonkin D, Korn JM, Flemming D, Jones MD, Antonakos B, Cooke VG, Steiger J, Ledell J, Stump MD, Sellers WR, et al. Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling. Cancer Research. 74: 3294-305. PMID 24747911 DOI: 10.1158/0008-5472.Can-14-0138-T  0.45
2014 Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, ... ... Sellers WR, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Molecular Cancer Therapeutics. 13: 1117-29. PMID 24608574 DOI: 10.1158/1535-7163.Mct-13-0865  0.443
2014 Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, ... ... Sellers WR, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nature Medicine. 20: 87-92. PMID 24362935 DOI: 10.1038/Nm.3435  0.359
2014 Wylie A, Schoepfer J, Berellini G, Cai H, Caravatti G, Cotesta S, Dodd S, Donovan J, Erb B, Furet P, Gangal G, Grotzfeld R, Hassan Q, Hood T, Iyer V, ... ... Sellers WR, et al. ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia Blood. 124: 398-398. DOI: 10.1182/Blood.V124.21.398.398  0.347
2014 Meyer SC, Keller MD, Koppikar P, Guryanova OA, Kleppe M, McKenney AS, Sellers WR, Hofmann F, Baffert F, Gaul C, Radimerski T, Levine RL. Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models Blood. 124: 160-160. DOI: 10.1182/Blood.V124.21.160.160  0.353
2014 Shao W, Schoumacher M, Hurov K, Lehar J, Yan-Neale Y, Mishina Y, Sonkin D, Korn J, Flemming D, Jones M, Antonakos B, Cooke V, Stump M, Danial N, Sellers W. Abstract LB-107: Inhibiting TNKS sensitizes KRAS mutant cancer cells to MEK inhibitors by suppressing FGFR2 feedback signaling Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-107  0.457
2014 Chan HM, Jaffe JD, Wang Y, Zhang J, Huether R, Kryukov GV, Bhang HC, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, McDonald ER, Wei L, Ma J, ... ... Sellers WR, et al. Abstract 2930: Global chromatin profiling reveals NSD2 mutation in pediatric ALL Cancer Research. 74: 2930-2930. DOI: 10.1158/1538-7445.Am2014-2930  0.613
2013 Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, ... ... Sellers WR, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proceedings of the National Academy of Sciences of the United States of America. 110: 20224-9. PMID 24277854 DOI: 10.1073/Pnas.1314239110  0.436
2013 Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, Pornon A, Romanet V, Guagnano V, Brümmendorf T, Sellers WR, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. Plos One. 8: e77652. PMID 24204904 DOI: 10.1371/Journal.Pone.0077652  0.423
2013 Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang HE, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, Robert McDonald E, Wei L, Ma J, ... ... Sellers WR, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nature Genetics. 45: 1386-91. PMID 24076604 DOI: 10.1038/Ng.2777  0.767
2013 Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, ... ... Sellers WR, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Research. 73: 6024-35. PMID 23928993 DOI: 10.1158/0008-5472.Can-13-1198  0.404
2013 Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discovery. 3: 1030-43. PMID 23842682 DOI: 10.1158/2159-8290.Cd-13-0142  0.378
2013 Stuart DD, Sellers WR. Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Nature Medicine. 19: 538-40. PMID 23652103 DOI: 10.1038/Nm.3195  0.434
2013 Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, Niu H, Billy E, Wartmann M, Ito M, Wilson CJ, Digan ME, Bauer A, Voshol H, Christofori G, ... Sellers WR, et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. Plos One. 8: e61916. PMID 23613971 DOI: 10.1371/Journal.Pone.0061916  0.361
2013 Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494: 251-5. PMID 23302800 DOI: 10.1038/Nature11814  0.303
2013 Cortés-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR, Hofmann F. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proceedings of the National Academy of Sciences of the United States of America. 110: 489-94. PMID 23267074 DOI: 10.1073/Pnas.1212780110  0.354
2013 Marais R, Sellers W, Livingston D, Mihich E. Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents. Cancer Research. 73: 1046-9. PMID 23222297 DOI: 10.1158/0008-5472.Can-12-3236  0.591
2013 Jaffe J, Wang Y, Chan H, Zhang J, Huether R, Kryukov G, Taylor J, Hu M, Englund N, Yan F, Wang Z, Wei L, Ma J, Easton J, Sellers WR, et al. Abstract PR01: Global chromatin profiling identifies NSD2 mutations in pediatric acute lymphoblastic leukemia Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-Pr01  0.607
2013 McMahon M, Thakur MD, Marsh V, Silva J, Landman A, Deuker M, Salangsang F, Pryer N, Phillips W, Levesque M, Dummer R, Bosenberg M, Sellers WR, Stuart D. Abstract SY17-03: Targeting BRAF and PI3′-kinase signaling for therapy of melanoma. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy17-03  0.434
2013 Thakur MD, Fisher R, Salangsang F, Landman A, Sellers W, Pryer N, Levesque MP, Dummer R, Gore M, Larkin J, McMahon M, Stuart D. Abstract LB-144: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-144  0.367
2013 Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, Parasuraman S, Howard S, Keen N, Sellers W, Brain C. Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pr02  0.465
2013 Barrett R, Guo R, Yuan J, Cooke V, Vattay A, Korn J, Liang G, Li X, Thiruvamoor R, Wylie A, Bric A, Keen N, Sellers W. Abstract C149: The PKC inhibitor Sotrastaurin selectively inhibits the growth of GNAQ mutant uveal melanoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C149  0.401
2012 Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, ... ... Sellers WR, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discovery. 2: 1118-33. PMID 23002168 DOI: 10.1158/2159-8290.Cd-12-0210  0.472
2012 Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. Plos One. 7: e44146. PMID 22952903 DOI: 10.1371/Journal.Pone.0044146  0.318
2012 Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA, Wagner S, Stamm C, Buness A, Chatenay-Rivauday C, Yao Y, He F, Lu CX, Guagnano V, Metz T, ... ... Sellers WR, et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discovery. 2: 948-59. PMID 22874768 DOI: 10.1158/2159-8290.Cd-12-0237  0.383
2012 Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, ... ... Sellers WR, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Molecular Cancer Therapeutics. 11: 1747-57. PMID 22653967 DOI: 10.1158/1535-7163.Mct-11-1021  0.353
2012 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Sellers WR, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483: 603-7. PMID 22460905 DOI: 10.1038/Nature11003  0.795
2012 Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK, Duhl D, Machajewski T, Sellers WR, Pryer NK, Gao Z. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Molecular Cancer Therapeutics. 11: 730-9. PMID 22246440 DOI: 10.1158/1535-7163.Mct-11-0667  0.327
2012 Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, ... ... Sellers WR, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Molecular Cancer Therapeutics. 11: 317-28. PMID 22188813 DOI: 10.1158/1535-7163.Mct-11-0474  0.401
2012 Sellers WR. Abstract PL01-01: The genetic basis for cancer therapeutics Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Pl01-01  0.457
2012 Porta DG, Guagnano V, Stamm C, Woehrle S, Kauffmann A, Yao Y, Brümmendorf T, Bordas V, Douget ML, Zhang Y, Chen Z, Ito M, Li F, Monahan J, Gaither A, ... ... Sellers W, et al. Abstract 854: Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials Cancer Research. 72: 854-854. DOI: 10.1158/1538-7445.Am2012-854  0.469
2012 Huet H, Schuller A, Li J, Johnson J, Dombrecht B, Meerschaert K, Cromie K, Bilic S, Li S, Garner A, Nunes S, Chopra R, Clark K, Yao M, Fawell S, ... ... Sellers WR, et al. Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches Cancer Research. 72: 3853-3853. DOI: 10.1158/1538-7445.Am2012-3853  0.391
2012 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, J.Wilson C, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Sellers WR, et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature. DOI: 10.1038/nature11735  0.6
2012 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S, Wilson C, Lehar J, Kryukov G, Murray L, Morrissey M, Sellers W, Schlegel R, Garraway L. 22 The Cancer Cell Line Encyclopedia - Using Preclinical Models to Predict Anticancer Drug Sensitivity European Journal of Cancer. 48: S5-S6. DOI: 10.1016/S0959-8049(12)70726-8  0.493
2011 Sellers WR. A blueprint for advancing genetics-based cancer therapy. Cell. 147: 26-31. PMID 21962504 DOI: 10.1016/J.Cell.2011.09.016  0.351
2011 Scholer-Dahirel A, Schlabach MR, Loo A, Bagdasarian L, Meyer R, Guo R, Woolfenden S, Yu KK, Markovits J, Killary K, Sonkin D, Yao YM, Warmuth M, Sellers WR, Schlegel R, et al. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proceedings of the National Academy of Sciences of the United States of America. 108: 17135-40. PMID 21949247 DOI: 10.1073/Pnas.1104182108  0.396
2011 Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy DA, Monahan JE, Jones MD, Blank J, Haasen D, Drueckes P, Wartmann M, McCarthy C, ... Sellers WR, et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Research. 71: 5255-64. PMID 21697284 DOI: 10.1158/0008-5472.Can-10-4433  0.388
2011 Caponigro G, Sellers WR. Advances in the preclinical testing of cancer therapeutic hypotheses. Nature Reviews. Drug Discovery. 10: 179-87. PMID 21358737 DOI: 10.1038/Nrd3385  0.398
2011 Kryukov GV, Berger MF, Stransky N, Barretina J, Onofrio R, Caponigro G, Sougnez C, Monahan J, Shefler E, Venkhatesan K, Cibulskis K, Morais P, Sivachenko A, Meltzer J, Lawrence M, ... ... Sellers W, et al. Abstract 923: Separating the wheat from the chaff: A first look at the Cancer Cell Lines Encyclopedia sequencing data Cancer Research. 71: 923-923. DOI: 10.1158/1538-7445.Am2011-923  0.632
2011 Barretina J, Stransky N, Caponigro G, Kim S, Margolin A, Venkhatesan K, Kryukov G, Berger M, Monahan J, Morais P, Meltzer J, Mahan S, Sonkin D, Raman P, Jones M, ... ... Sellers W, et al. Abstract 5455: Integrative analysis of the Cancer Cell Line Encyclopedia reveals genetic and transcriptional predictors of compound sensitivity Cancer Research. 71: 5455-5455. DOI: 10.1158/1538-7445.Am2011-5455  0.693
2011 Porta DG, Guagnano V, Yao Y, Kauffmann A, Stamm C, Chen Z, Zhang Y, Bordas V, Douget ML, Ito M, Li F, Monahan J, Gaither A, Borawski J, Wilson CJ, ... ... Sellers WR, et al. Abstract C193: FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a novel orally bioavailable, selective, and potent FGFR inhibitor. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C193  0.45
2011 Liu J, Pan S, Sun F, Kasibhatla S, Schuller A, Li A, Li C, Cui X, Wang T, Villarroel M, Mclaughlin M, Sellers W, Boral A, Harris J. PD08-11: Targeting Porcupine, a Critical Node for Wnt Signalling in Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd08-11  0.421
2010 Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, ... ... Sellers WR, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 468: 968-72. PMID 21107320 DOI: 10.1038/Nature09627  0.74
2010 Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, ... ... Sellers WR, et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nature Medicine. 16: 1429-33. PMID 21076395 DOI: 10.1038/Nm.2251  0.387
2010 Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, ... ... Sellers WR, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Science Translational Medicine. 2: 51ra70. PMID 20881279 DOI: 10.1126/Scitranslmed.3001599  0.387
2010 Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, ... ... Sellers WR, et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proceedings of the National Academy of Sciences of the United States of America. 107: 15473-8. PMID 20713706 DOI: 10.1073/Pnas.1007428107  0.315
2010 Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Research. 70: 6804-14. PMID 20699365 DOI: 10.1158/0008-5472.Can-10-0409  0.415
2010 Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, ... ... Sellers WR, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics. 42: 715-21. PMID 20601955 DOI: 10.1038/Ng.619  0.802
2010 Jagani Z, Wiederschain D, Loo A, He D, Mosher R, Fordjour P, Monahan J, Morrissey M, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M. The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Research. 70: 5528-38. PMID 20530672 DOI: 10.1158/0008-5472.Can-09-4229  0.357
2010 Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clinical Pharmacology and Therapeutics. 87: 543-52. PMID 20237469 DOI: 10.1038/Clpt.2009.297  0.345
2010 Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, ... ... Sellers WR, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 463: 899-905. PMID 20164920 DOI: 10.1038/Nature08822  0.81
2010 Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA. An oncogenic role for ETV1 in melanoma. Cancer Research. 70: 2075-84. PMID 20160028 DOI: 10.1158/0008-5472.Can-09-3092  0.587
2010 Venkatesan K, Stransky N, Margolin A, Reddy A, Raman P, Sonkin D, Jones M, Wilson C, Kim S, Warmuth M, Sellers W, Lehar J, Barretina J, Caponigro G, Garraway L, et al. Prediction of drug response using genomic signatures from the Cancer Cell Line Encyclopedia Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-Pr2  0.583
2010 Sellers WR. Abstract DD01-04: NVP-BKM120: A selective inhibitor of type I PI3 kinases Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Dd01-04  0.426
2010 Voliva cF, Pecchi S, Burger M, Nagel T, Schnell C, Fritsch c, Brachmann s, Menezes D, Knapp M, Shoemaker K, Wiesmann M, Huh k, Zaror I, Dorsch M, Sellers WR, et al. Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials Cancer Research. 70: 4498-4498. DOI: 10.1158/1538-7445.Am10-4498  0.439
2010 Maira M, Menezes D, Pecchi S, Shoemaker K, Burger M, Schnell c, Fritsch c, Brachmann S, Nagel T, Sellers WR, Garcia-Echeverria C, Wiesmann M, Voliva cF. Abstract 4497: NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models Cancer Research. 70: 4497-4497. DOI: 10.1158/1538-7445.Am10-4497  0.429
2010 Buonamici S, Ospina BE, Zhu JX, Yuan J, Hsiao K, Vattay A, Li F, Deeds J, Ostrom L, Monahan J, Williams J, Kelleher J, Peukert S, Pan S, Wu X, ... ... Sellers WR, et al. Abstract 4290: The smoothened antagonist NVP-LDE225 targets stroma and cancer stem cells in primary human pancreatic tumor xenografts Cancer Research. 70: 4290-4290. DOI: 10.1158/1538-7445.Am10-4290  0.434
2010 Jane-Valbuena J, Widlund H, Perner S, Johnson L, Dibner A, Lin W, Baker A, Nazarian R, Vijayendran K, Sellers W, Hahn W, Duncan L, Rubin M, Fisher D, Garraway LA. Abstract 3111: The ETS factor ETV1 is an oncogene in melanoma Cancer Research. 70: 3111-3111. DOI: 10.1158/1538-7445.Am10-3111  0.591
2010 Barretina J, Caponigro G, Kim S, Stransky N, Venkhatesan K, Reddy V, Berger M, Morrissey M, Morais P, Meltzer J, Thibault J, Mahan S, Sonkin D, Che J, Raman P, ... ... Sellers W, et al. Abstract 2620: The Cancer Cell Line Encyclopedia project: From integrative cancer genomics to personalized cancer therapy Cancer Research. 70: 2620-2620. DOI: 10.1158/1538-7445.Am10-2620  0.71
2010 Dorsch M, Buonamici S, Williams J, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Ostrom L, Fordjour P, Anderson D, Morrissey M, Monahan J, Kelleher J, Peukert S, ... ... Sellers W, et al. Abstract 1976: The discovery of mechanisms of resistance to SMO antagonists and the therapeutic implications Cancer Research. 70: 1976-1976. DOI: 10.1158/1538-7445.Am10-1976  0.434
2010 Stransky N, Venkhatesan K, Morrissey M, Barretina J, Raman P, Getz G, Berger M, Johannessen C, Callahan A, Morais P, Mahan S, Gupta S, Onofrio R, Sougnez C, Winckler W, ... ... Sellers W, et al. Abstract 105: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia Cancer Research. 70: 105-105. DOI: 10.1158/1538-7445.Am10-105  0.698
2010 Stransky N, Venkatesan K, Barretina J, Caponigro G, Margolin A, Morrissey M, Raman P, Getz G, Berger M, Johannessen C, Callahan A, Morais P, Mahan S, Gupta S, Onofrio R, ... ... Sellers W, et al. Abstract PR4: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Pr4  0.687
2010 Zhang J, Li J, Li Z, Doshi S, Chen Y, Li X, Ruddy D, Fordjour P, Monahan J, Feng F, Zhu P, Mchenry K, Slisz J, Zhang X, Tan L, ... ... Sellers W, et al. Abstract A54: shRNA screens in cancer cells revealed cell-context dependent cross-talk between RAF-MEK-ERK pathway and DR5 mediated apoptosis Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-A54  0.437
2009 Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America. 106: 20411-6. PMID 19915144 DOI: 10.1073/Pnas.0905833106  0.558
2009 Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, ... ... Sellers WR, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 18351-6. PMID 19805051 DOI: 10.1073/Pnas.0907325106  0.618
2009 Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R, Meyerson M. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. British Journal of Cancer. 101: 1218-9; author reply. PMID 19738612 DOI: 10.1038/Sj.Bjc.6605301  0.635
2009 Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, Garraway LA, Sellers WR. p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Molecular and Cellular Biology. 29: 5377-88. PMID 19635806 DOI: 10.1128/Mcb.01649-08  0.547
2009 Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, ... ... Sellers WR, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 16: 21-32. PMID 19573809 DOI: 10.1016/J.Ccr.2009.04.012  0.625
2009 Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Research. 69: 4674-81. PMID 19470766 DOI: 10.1158/0008-5472.Can-09-0146  0.712
2009 Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Research. 69: 4286-93. PMID 19401449 DOI: 10.1158/0008-5472.Can-08-4765  0.43
2009 Stuart D, Sellers WR. Linking somatic genetic alterations in cancer to therapeutics. Current Opinion in Cell Biology. 21: 304-10. PMID 19328671 DOI: 10.1016/J.Ceb.2009.02.001  0.394
2009 Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, ... ... Sellers WR, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 106: 4834-9. PMID 19261849 DOI: 10.1073/Pnas.0806514106  0.738
2009 Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, ... ... Sellers W, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1417-27. PMID 19193619 DOI: 10.1158/1078-0432.Ccr-08-1564  0.674
2009 Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, Chen Y, Caponigro G, Yao YM, Lengauer C, Sellers WR, Benson JD. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle (Georgetown, Tex.). 8: 498-504. PMID 19177017 DOI: 10.4161/Cc.8.3.7701  0.431
2009 Sellers WR. Abstract PL02-01: Targeting the PI3K pathway in cancer Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-Pl02-01  0.438
2009 Sellers W. The Development of PI3K Pathway Modulators for Cancer. Cancer Research. 69. DOI: 10.1158/0008-5472.Sabcs-09-P2-1  0.419
2008 Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 27: 5511-26. PMID 18794885 DOI: 10.1038/Onc.2008.246  0.418
2008 Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, ... ... Sellers WR, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Research. 68: 6779-88. PMID 18701503 DOI: 10.1158/0008-5472.Can-08-0742  0.783
2008 Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, ... ... Sellers WR, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 14: 146-55. PMID 18691549 DOI: 10.1016/J.Ccr.2008.06.002  0.382
2008 Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, ... Sellers W, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics. 7: 1851-63. PMID 18606717 DOI: 10.1158/1535-7163.Mct-08-0017  0.405
2008 Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, ... ... Sellers WR, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 105: 8713-7. PMID 18552176 DOI: 10.1073/Pnas.0803379105  0.525
2008 Li C, Beroukhim R, Weir BA, Winckler W, Garraway LA, Sellers WR, Meyerson M. Major copy proportion analysis of tumor samples using SNP arrays. Bmc Bioinformatics. 9: 204. PMID 18426588 DOI: 10.1186/1471-2105-9-204  0.685
2008 Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Molecular and Cellular Biology. 28: 3281-9. PMID 18332125 DOI: 10.1128/Mcb.00310-08  0.391
2008 Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Research. 36: 2446-56. PMID 18304946 DOI: 10.1093/Nar/Gkn089  0.645
2008 Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research. 68: 664-73. PMID 18245465 DOI: 10.1158/0008-5472.Can-07-2615  0.728
2008 Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 32: 307-16. PMID 18202752 DOI: 10.3892/Ijo.32.2.307  0.647
2008 Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel Cancer Research. 68: 589-596. PMID 18199556 DOI: 10.1158/0008-5472.Can-07-1570  0.355
2007 Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, Sage D, Slisz J, Tran M, Straub C, Ramsey T, Iourgenko V, Huang A, Chen Y, Schlegel R, ... ... Sellers WR, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Research. 67: 11493-8. PMID 18089776 DOI: 10.1158/0008-5472.Can-07-5173  0.336
2007 Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, ... ... Sellers WR, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 104: 20007-12. PMID 18077431 DOI: 10.1073/Pnas.0710052104  0.8
2007 Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, Sellers WR. Identification of prostate cancer modifier pathways using parental strain expression mapping. Proceedings of the National Academy of Sciences of the United States of America. 104: 17771-6. PMID 17978178 DOI: 10.1073/Pnas.0708476104  0.403
2007 Hill AD, Chang BS, Hill RS, Garraway LA, Bodell A, Sellers WR, Walsh CA. A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome. American Journal of Medical Genetics. Part A. 143: 1692-8. PMID 17603806 DOI: 10.1002/Ajmg.A.31776  0.466
2007 Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Sellers WR, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/Ng1975  0.805
2007 Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson M, Wong WH, Sellers WR, et al. Correction: Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays Plos Computational Biology. 3: e40. DOI: 10.1371/Journal.Pcbi.0030040  0.661
2007 Garraway LA, Sellers WR. The authors reply [2] Nature Reviews Cancer. 7: 1P. DOI: 10.1038/Nrc1947-C2  0.472
2007 Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, Wang M, Feng W, Zander T, MacConnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, ... ... Sellers WR, et al. Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer Nature Genetics. 39: 567-567. DOI: 10.1038/Ng0407-567A  0.715
2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, ... ... Sellers WR, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/Journal.Pmed.0030485  0.637
2006 Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, ... Sellers WR, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Research. 66: 8337-41. PMID 16951139 DOI: 10.1158/0008-5472.Can-06-1482  0.643
2006 Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nature Reviews. Cancer. 6: 593-602. PMID 16862190 DOI: 10.1038/Nrc1947  0.571
2006 Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, ... ... Sellers WR, et al. Development of an integrated prostate cancer research information system. Clinical Genitourinary Cancer. 5: 61-6. PMID 16859581 DOI: 10.3816/Cgc.2006.N.019  0.314
2006 Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, ... ... Sellers WR, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Medicine. 12: 852-5. PMID 16799556 DOI: 10.1038/Nm1437  0.664
2006 Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, Sellers WR, Lengauer C. Validating cancer drug targets. Nature. 441: 451-6. PMID 16724057 DOI: 10.1038/Nature04873  0.344
2006 Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson M, Wong WH, Sellers WR, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. Plos Computational Biology. 2: e41. PMID 16699594 DOI: 10.1371/Journal.Pcbi.0020041  0.689
2006 Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Research. 66: 3162-8. PMID 16540667 DOI: 10.1158/0008-5472.Can-05-3757  0.557
2006 Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M, Devreotes PN. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America. 103: 3633-8. PMID 16537447 DOI: 10.1073/Pnas.0510570103  0.304
2006 Garraway LA, Sellers WR. From integrated genomics to tumor lineage dependency. Cancer Research. 66: 2506-8. PMID 16510564 DOI: 10.1158/0008-5472.Can-05-4604  0.613
2006 Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 439: 358-62. PMID 16273091 DOI: 10.1038/Nature04304  0.546
2006 Garraway LA, Sellers WR. Erratum: Lineage dependency and lineage-survival oncogenes in human cancer Nature Reviews Cancer. 6: 742-742. DOI: 10.1038/Nrc1972  0.55
2006 Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, ... ... Sellers WR, et al. Erratum: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing (Nature Medicine (2006) 12 (852-855)) Nature Medicine. 12. DOI: 10.1038/Nm1006-1220A  0.631
2005 Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harbor Symposia On Quantitative Biology. 70: 73-81. PMID 16869740 DOI: 10.1101/Sqb.2005.70.056  0.572
2005 Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. "Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harbor Symposia On Quantitative Biology. 70: 25-34. PMID 16869735 DOI: 10.1101/Sqb.2005.70.016  0.747
2005 Weir B, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee J, Janne P, Li C, Sellers W, Naoki K, Richards W, Sugarbaker D, Chen F, Rubin M, et al. High resolution SNP arrays identify amplified regions in lung cancer Cancer Biology and Therapy. 4. PMID 16710933 DOI: 10.4161/cbt.4.8.2003  0.595
2005 Mihich E, Sellers WR. Seventeenth Annual Pezcoller Symposium: molecular understanding of solid tumors. Cancer Research. 65: 11251-4. PMID 16357127 DOI: 10.1158/0008-5472.Can-05-2920  0.37
2005 LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, Harrington D, Sellers WR, Meyerson M. Allele-specific amplification in cancer revealed by SNP array analysis. Plos Computational Biology. 1: e65. PMID 16322765 DOI: 10.1371/Journal.Pcbi.0010065  0.635
2005 Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene. 24: 7465-74. PMID 16288293 DOI: 10.1038/Sj.Onc.1209096  0.408
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, ... ... Sellers WR, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/Nejmoa051918  0.552
2005 Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Research. 65: 8968-74. PMID 16204070 DOI: 10.1158/0008-5472.Can-05-1829  0.515
2005 Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. Plos Medicine. 2: e313. PMID 16187797 DOI: 10.1371/Journal.Pmed.0020313  0.522
2005 Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, ... Sellers WR, et al. Amplification and overexpression of prosaposin in prostate cancer. Genes, Chromosomes & Cancer. 44: 351-64. PMID 16080200 DOI: 10.1002/Gcc.20249  0.56
2005 Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, ... ... Sellers WR, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 436: 117-22. PMID 16001072 DOI: 10.1038/Nature03664  0.756
2005 Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jänne PA, Girard L, ... ... Sellers WR, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Research. 65: 5561-70. PMID 15994928 DOI: 10.1158/0008-5472.Can-04-4603  0.683
2005 Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, ... ... Sellers WR, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7: 387-97. PMID 15837627 DOI: 10.1016/J.Ccr.2005.03.023  0.501
2005 Krützfeldt M, Ellis M, Weekes DB, Bull JJ, Eilers M, Vivanco MD, Sellers WR, Mittnacht S. Selective ablation of retinoblastoma protein function by the RET finger protein. Molecular Cell. 18: 213-24. PMID 15837424 DOI: 10.1016/J.Molcel.2005.03.009  0.347
2005 Sellers WR, Meyerson M. EGFR gene mutations: a call for global x global views of cancer. Journal of the National Cancer Institute. 97: 326-8. PMID 15741561 DOI: 10.1093/Jnci/Dji079  0.568
2005 Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson ML, Wong W, Sellers WR, et al. Inferring Loss-of-Heterozygosity from Tumors Without Paired Normals Using High-Density SNP Arrays Plos Computational Biology. DOI: 10.1371/Journal.Pcbi.0020041.Eor  0.603
2005 Masciari S, Harris L, Branda K, Petkovska A, Paez J, Haber D, Digianni L, Sellers W, Li F, Garber J. Germline TP53 mutations in women with very early onset breast cancer (BR) Journal of Clinical Oncology. 23: 1015-1015. DOI: 10.1200/Jco.2005.23.16_Suppl.1015  0.306
2005 Garraway LA, Sellers WR. Array-based approaches to cancer genome analysis Drug Discovery Today: Disease Mechanisms. 2: 171-177. DOI: 10.1016/J.Ddmec.2005.05.020  0.553
2004 Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Research. 64: 8867-75. PMID 15604246 DOI: 10.1158/0008-5472.Can-04-2938  0.305
2004 Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, ... ... Sellers WR, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Research. 64: 8816-20. PMID 15604238 DOI: 10.1158/0008-5472.Can-04-1923  0.525
2004 Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, et al. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Molecular Cancer Research : McR. 2: 489-94. PMID 15383627  0.443
2004 Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell. 6: 263-74. PMID 15380517 DOI: 10.1016/J.Ccr.2004.06.027  0.545
2004 Korkmaz CG, Korkmaz KS, Manola J, Xi Z, Risberg B, Danielsen H, Kung J, Sellers WR, Loda M, Saatcioglu F. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. The Journal of Urology. 172: 1134-9. PMID 15311057 DOI: 10.1097/01.Ju.0000136526.78535.B8  0.308
2004 Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 6: 17-32. PMID 15261139 DOI: 10.1016/J.Ccr.2004.06.010  0.571
2004 Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2954-63. PMID 15254063 DOI: 10.1200/Jco.2004.02.141  0.478
2004 Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, ... ... Sellers WR, et al. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 104: 1855-8. PMID 15178581 DOI: 10.1182/Blood-2004-02-0712  0.644
2004 Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Research. 64: 3814-22. PMID 15172988 DOI: 10.1158/0008-5472.Can-03-3881  0.568
2004 Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine. 10: 594-601. PMID 15156201 DOI: 10.1038/Nm1052  0.365
2004 Paez JG, Lin M, Beroukhim R, Lee JC, Zhao X, Richter DJ, Gabriel S, Herman P, Sasaki H, Altshuler D, Li C, Meyerson M, Sellers WR. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Research. 32: e71. PMID 15150323 DOI: 10.1093/Nar/Gnh069  0.614
2004 Zhao X, Li C, Paez JG, Chin K, Jänne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Research. 64: 3060-71. PMID 15126342 DOI: 10.1158/0008-5472.Can-03-3308  0.548
2004 Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, N.Y.). 304: 1497-500. PMID 15118125 DOI: 10.1126/Science.1099314  0.546
2004 Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics (Oxford, England). 20: 1233-40. PMID 14871870 DOI: 10.1093/Bioinformatics/Bth069  0.325
2004 Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, Scaringe S, Sellers WR. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Research. 32: 893-901. PMID 14769947 DOI: 10.1093/Nar/Gkh238  0.352
2004 Taplin M, George DJ, Halabi S, Sellers WR, Sanford B, Hennessy KT, Mihos CG, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480 Journal of Clinical Oncology. 22: 4557-4557. DOI: 10.1200/Jco.2004.22.90140.4557  0.304
2003 Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 4: 463-76. PMID 14706338 DOI: 10.1016/S1535-6108(03)00303-9  0.371
2003 Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, et al. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. The Journal of Urology. 170: S3-5. PMID 14610403 DOI: 10.1097/01.Ju.0000095101.18470.A0  0.317
2003 Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 4: 147-58. PMID 12957289 DOI: 10.1016/S1535-6108(03)00187-9  0.553
2003 Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Research. 63: 4781-5. PMID 12941794  0.45
2003 Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proceedings of the National Academy of Sciences of the United States of America. 100: 7841-6. PMID 12799464 DOI: 10.1073/Pnas.1232229100  0.303
2002 Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell. 2: 349-50. PMID 12450788 DOI: 10.1016/S1535-6108(02)00187-3  0.356
2002 Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell. 2: 81-91. PMID 12150827 DOI: 10.1016/S1535-6108(02)00086-7  0.358
2002 Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1: 203-9. PMID 12086878 DOI: 10.1016/S1535-6108(02)00030-2  0.355
2002 DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M, Brown M. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Research. 62: 89-98. PMID 11782364  0.486
2001 Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. The Journal of Biological Chemistry. 276: 48627-30. PMID 11707428 DOI: 10.1074/Jbc.C100556200  0.303
2000 Siegert JL, Rushton JJ, Sellers WR, Kaelin WG, Robbins PD. Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene. 19: 5703-11. PMID 11126356 DOI: 10.1038/Sj.Onc.1203966  0.529
2000 Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Molecular and Cellular Biology. 20: 8969-82. PMID 11073996 DOI: 10.1128/Mcb.20.23.8969-8982.2000  0.381
2000 Miyake S, Sellers WR, Safran M, Li X, Zhao W, Grossman SR, Gan J, DeCaprio JA, Adams PD, Kaelin WG. Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Molecular and Cellular Biology. 20: 8889-902. PMID 11073989 DOI: 10.1128/Mcb.20.23.8889-8902.2000  0.68
2000 Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. The Journal of Biological Chemistry. 275: 39223-30. PMID 11010972 DOI: 10.1074/Jbc.M007291200  0.371
2000 Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function Molecular and Cellular Biology. 20: 5010-5018. PMID 10866658 DOI: 10.1128/Mcb.20.14.5010-5018.2000  0.331
2000 Vazquez F, Sellers WR. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3- kinase signaling Biochimica Et Biophysica Acta - Reviews On Cancer. 1470: M21-M35. PMID 10656987 DOI: 10.1016/S0304-419X(99)00032-3  0.323
2000 Ramaswamy S, Sellers WR. PTEN: A prostate cancer tumor-suppressor gene Prostate Journal. 2: 55-61. DOI: 10.1046/J.1525-1411.2000.22001.X  0.379
1999 Sellers WR, Fisher DE. Apoptosis and cancer drug targeting Journal of Clinical Investigation. 104: 1655-1661. PMID 10606616 DOI: 10.1172/Jci9053  0.405
1999 Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/akt pathway Proceedings of the National Academy of Sciences of the United States of America. 96: 2110-2115. PMID 10051603 DOI: 10.1073/Pnas.96.5.2110  0.426
1999 Adams PD, Li X, Sellers WR, Baker KB, Leng X, Harper JW, Taya Y, Kaelin WG. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Molecular and Cellular Biology. 19: 1068-80. PMID 9891042 DOI: 10.1128/Mcb.19.2.1068  0.53
1998 Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB, Kaelin WG. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes & Development. 12: 95-106. PMID 9420334 DOI: 10.1101/Gad.12.1.95  0.564
1997 Sellers WR, Kaelin WG. Role of the retinoblastoma protein in the pathogenesis of human cancer Journal of Clinical Oncology. 15: 3301-3312. PMID 9363859 DOI: 10.1200/Jco.1997.15.11.3301  0.62
1997 Adams PD, Lopez P, Sellers WR, Kaelin WG. Fluorescence-activated cell sorting of transfected cells Methods in Enzymology. 283: 59-72. PMID 9251011 DOI: 10.1016/S0076-6879(97)83007-8  0.509
1996 Neuman E, Sellers WR, McNeil JA, Lawrence JB, Kaelin WG. Structure and partial genomic sequence of the human E2F1 gene. Gene. 173: 163-9. PMID 8964493 DOI: 10.1016/0378-1119(96)00184-9  0.561
1996 Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors Molecular and Cellular Biology. 16: 6623-6633. PMID 8943316 DOI: 10.1128/Mcb.16.12.6623  0.535
1996 Grafi G, Burnett RJ, Helentjaris T, Larkins BA, Decaprio JA, Sellers WR, Kaelin WG. A maize cDNA encoding a member of the retinoblastoma protein family: Involvement in endoreduplication Proceedings of the National Academy of Sciences of the United States of America. 93: 8962-8967. PMID 8799136 DOI: 10.1073/Pnas.93.17.8962  0.664
1996 Sellers WR, Kaelin WG. RB [corrected] as a modulator of transcription Biochimica Et Biophysica Acta. 1288: M1-5. PMID 8764839 DOI: 10.1016/0304-419X(96)00014-5  0.545
1996 Sellers WR, Kaelin WG. Erratum to ‘RB as a modulator of transcription’ [Biochim. Biophys. Acta 1288 (1996) M1–M5] Biochimica Et Biophysica Acta (Bba) - Reviews On Cancer. 1288: E1. DOI: 10.1016/S0304-419X(96)00035-2  0.451
1996 Sellers WR, Kaelin WG. xRB as a modulator of transcription Biochimica Et Biophysica Acta - Reviews On Cancer. 1288: M1-M5. DOI: 10.1016/0304-419X(96)00014-5  0.414
1995 Sellers WR, Rodgers JW, Kaelin WG. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites Proceedings of the National Academy of Sciences of the United States of America. 92: 11544-11548. PMID 8524800 DOI: 10.1073/Pnas.92.25.11544  0.515
1995 Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin WG. The transcription factor E2F-1 is a downstream target of RB action. Molecular and Cellular Biology. 15: 742-55. PMID 7823942 DOI: 10.1128/Mcb.15.2.742  0.744
1995 Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 375: 694-8. PMID 7791904 DOI: 10.1038/375694A0  0.543
1995 Neuman E, Flemington EK, Sellers WR, Kaelin WG. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter Molecular and Cellular Biology. 15: 4660. PMID 7623859  0.463
1994 Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell. 77: 799-800. PMID 8004670 DOI: 10.1016/0092-8674(94)90127-9  0.463
1994 Neuman E, Flemington EK, Sellers WR, Kaelin WG. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Molecular and Cellular Biology. 14: 6607-15. PMID 7935380 DOI: 10.1128/Mcb.14.10.6607  0.542
1994 Eckner R, Arany Z, Ewen M, Sellers W, Livingston DM. The adenovirus E1A-associated 300-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionarily conserved family Cold Spring Harbor Symposia On Quantitative Biology. 59: 85-95. PMID 7587135 DOI: 10.1101/Sqb.1994.059.01.012  0.661
1992 Kaelin WG, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell. 70: 351-64. PMID 1638635 DOI: 10.1016/0092-8674(92)90108-O  0.646
Show low-probability matches.